Compositions for inhibiting 3' repair exonuclease 2 and methods of screening for such compositions

Abstract

Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.

What is claimed is: 
     
         1 . A therapeutically effective pharmaceutical composition comprising 4-benzoyl methyphenyl (2-nitrophenoxy) acetate, or pharmaceutically acceptable derivatives thereof. 
     
     
         2 . A method for increasing effectiveness of a chemotherapeutic agent in a mammalian cancer cell, the method comprising of
 administering to a mammalian cancer cell exposed to the chemotherapeutic agent, a therapeutically effective pharmaceutical composition containing 4-benzoyl-2-methyphenyl (2-nitrophenoxy) acetate, or pharmaceutically acceptable derivatives thereof.   
     
     
         3 . A therapeutically effective pharmaceutical composition comprising N-benzyl-2-([bis(furan-2-yl)-1,2,4-triazin-3-yl]sulfanyl) acetamide, or pharmaceutically acceptable derivatives thereof. 
     
     
         4 . A method for increasing effectiveness of a chemotherapeutic agent in a mammalian cancer cell, the method comprising of
 administering to a mammalian cancer cell exposed to the chemotherapeutic agent, a therapeutically effective pharmaceutical composition containing N-benzyl-2-([bis(furan-2-yl)-1,2,4-triazin-3-yl]sulfanyl) acetamide, or pharmaceutically acceptable derivatives thereof.   
     
     
         5 . A therapeutically effective pharmaceutical composition comprising 6-(benzylcarbamoyl)-1-methycyclohex-3-ene-1-carboxylic acid, or pharmaceutically acceptable derivatives thereof. 
     
     
         6 . A method for increasing effectiveness of a chemotherapeutic agent in a mammalian cancer cell, the method comprising of
 administering to a mammalian cancer cell exposed to the chemotherapeutic agent, a therapeutically effective pharmaceutical composition containing 6-(benzylcarbamoyl)-1-methycyclohex-3-ene-1-carboxylic acid, or pharmaceutically acceptable derivatives thereof.   
     
     
       7. A therapeutically effective pharmaceutical composition comprising 8-(phenylamino)naphthalene-1-sulfonic acid, or pharmaceutically acceptable derivatives thereof. 
     
     
         8 . A method for increasing effectiveness of a chemotherapeutic agent in a mammalian cancer cell, the method comprising of
 administering to a mammalian cancer cell exposed to the chemotherapeutic agent, a therapeutically effective pharmaceutical composition containing 8-(phenylamino) naphthalene-1-sulfonic acid, or pharmaceutically acceptable derivatives thereof.   
     
     
         9 . A therapeutically effective pharmaceutical composition comprising benzyl 6-(furan-2-yl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate, or pharmaceutically acceptable derivatives thereof. 
     
     
         10 . A method for increasing effectiveness of a chemotherapeutic agent in a mammalian cancer cell, the method comprising of
 administering to a mammalian cancer cell exposed to the chemotherapeutic agent, a therapeutically effective pharmaceutical composition containing benzyl 6-(furan-2-yl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate, or pharmaceutically acceptable derivatives thereof.